CLINICAL EXPERIENCE ON CEFIXIME, A NEW ORAL CEPHALOSPORIN, IN THE FIELD OF INTERNAL MEDICINE

• Published in: CHEMOTHERAPY Vol. 33; no. Supplement6; pp. 393 - 400
• Main Authors: YAMADA, YOSHIO, KOBAYASHI, KEIJI, SHIOTA, KENZO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1985; 公益社団法人 日本化学療法学会
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.33.Supplement6_393

This study was carried out to evaluate the therapeutic efficacy and safety of cefixime (CFIX) in the field of internal medicine. CFIX was given orally to 13 patients in a dose of 100mg twice daily for 4-22 days (average: 11.7 days). The subjects consisted of 12 patients with respiratory tract infection and 1 with urinary tract infection; 3 with pharyngolaryngitis, 1 with tonsillitis, 2 with acute bronchitis, 2 with acute exacerbation of chronic bronchitis, 3 with pneumonia, 1 with infected lung cancer and 1 with acute cystitis. The overall effect of CFIX was “excellent” in 2, “good” in 8 and “fair” in 3, with an effectiveness rate of 76.9%. The causative organisms were identified as E. coli in 2 patients, which were eradicated after treatment with CFIX. No side effects or abnormal laboratory data were observed in any of the 13 patients. Considering its broad spectrum, prolonged serum level and clinical results, it was concluded that CFIX is an oral antibiotic of first choice which is highly useful for the treatment of infections in the field of internal medicine.